Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

14.10.2022 - - Enzo Life Sciences reports revenue of $32.6 million and 8% growth in FY 2022, net of FX - Company successfully launched AMPIVIEW gene expression platform powered by LoopRNA ISH technology - Continues to engage with ...

Related Keywords

New York ,United States ,Farmingdale ,Long Island ,Enzo Loop ,Matthew Kupferberg ,Lynn Granito ,Chris Calabrese ,Hamid Erfanian ,Enzo Biochem ,Lifesci Advisors ,Linkedin ,Enzo Clinical Lab ,Enzo Life Sciences ,Company Form ,Enzo Clinical Laboratory ,Berry Company Public Relations ,York State Department Of Health ,Enzo Biochem Inc ,Securities Exchange ,United States Centers For Disease ,Paycheck Protection Program ,Lab Developed ,Enzo Diagnostics ,Emergency Use ,United States Centers ,Disease Control ,General Counsel ,New York State Department ,Ann Arbor ,Life Sciences ,Clinical Lab ,Eastern Standard Time ,Investor Relations ,Sarbanes Oxley Act ,Securities Act ,Securities Exchange Act ,Risk Factors ,Sci Advisors ,Protection Program ,Shares Outstanding ,